A-A+ Home | Print | Email | Add This | Adjust text size

The Facts About Barrett's Esophagus and GERD

Just want the facts?

Here's a list of notable information about Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD).

  • Barrett’s Esophagus is a complication of Gastroesophageal Reflux Disease (GERD).

  • Barrett’s Esophagus is considered a precursor to esophageal adenocarcinoma.

  • GERD affects an estimated 25%-35% of the US population (7%-10% with daily symptoms).

  • 10%-20% of patients with chronic GERD symptoms have Barrett’s Esophagus.

  • 44% of Barrett’s patients lack consistent severe GERD symptoms.

  • Barrett’s Esophagus patients have 30-125 times greater risk of developing esophageal cancer.

  • The incidence of esophageal adenocarcinoma is rising more rapidly than any other cancer, six fold increase from 1975 to 2001.

  • The prevalence of Barrett’s Esophagus in general population is 1.6%, approximately 3.3 million in the United States. In an endoscopic series of patients, 0.9%-4.5% had Barrett’s Esophagus.

  • The prevalence of Cancer, High Grade Dysplasia, and Low Grade Dysplasia in Barrett’s Esophagus are 6.7%, 3.0%, and 7.3%, respectively.

  • The incidence rate of Cancer, High Grade Dysplasia, and Low Grade Dysplasia in Barrett’s Esophagus are 0.5%, 0.9% and 4.3% per year, respectively.

  • 5% of patients with Barrett’s Esophagus develop esophageal cancer within 5-8 years of diagnosis.

  • The incidence of High Grade Dysplasia progressing to cancer is 10% (range 6%-19%) per year.

  • The incidence of Low Grade Dysplasia progressing to cancer is 0.6% per year.

  • 53% of patients with Cancer/High Grade Dysplasia have no dysplasia at their 1st two scopes.

  • Short segment Barrett’s (≤ 3 cm) is 3 times more common than long segment Barrett’s Esophagus.

  • Genetic variation in two chromosomes have been linked to development of Barrett’s Esophagus.

  • Risk of mortality from esophagectomy for Barrett’s Esophagus is 2% (range of 0-4%).

  • 5-year survival rate for late stage esophageal adenocarcinoma is approximately 13%.